TriSalus Life Sciences, Inc. (TLSI)

Market Cap	240.93M +39.6%
Revenue (ttm)	45.15M +53.4%
Net Income	-69.69M
EPS	-1.84
Shares Out	61.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	366,808
Open	3.870
Previous Close	3.860
Day's Range	3.750 - 3.930
52-Week Range	3.420 - 7.950
Beta	0.44
Analysts	Strong Buy
Price Target	7.00 (+78.12%)
Earnings Date	Mar 5, 2026

About TLSI

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSI
• Website: https://trisaluslifesci.com

Financial Performance

In 2025, TriSalus Life Sciences's revenue was $45.15 million, an increase of 53.41% compared to the previous year's $29.43 million. Losses were -$69.69 million, 109.7% more than in 2024.

Analyst Summary

According to one analyst, the rating for TLSI stock is "Strong Buy" and the 12-month stock price target is $7.0.

Price Target

$7.0

(78.12% upside)

Analyst Consensus: Strong Buy